Kaitlin Harbour Lampson

Ms. Kaitlin Harbour Lampson

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in JAMA Oncology
Verified
Journal Article
Closed access
KLKevin T T. Liou
Kevin T T. Liou
SCSigrid Carlsson
Sigrid Carlsson
DADivya Ajay
Divya Ajay
JSJaspreet S. Sandhu
Jaspreet S. Sandhu
YLYuelin Li
Yuelin Li
JMJun J. Mao
Jun J. Mao
This pilot randomized clinical trial evaluates acupuncture relative to usual care for the treatment of nocturia in survivors of prostate cancer.

1 January 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
XLXiaotong Li
Xiaotong Li
KLKaitlin Harbour Lampson
Kaitlin Harbour Lampson
TATim A Ahles
Tim A Ahles
JRJames C Root
James C Root
LLLi Li
Li Li
KLKevin T T. Liou
Kevin T T. Liou
(1) Background: This pilot study evaluates the feasibility and preliminary effects of acupuncture for cancer-related cognitive dysfunction (CRCD) in cancer survivors. (2) Methods: A randomized trial comparing real acupuncture (RA) to sham acupuncture (SA) and waitlist control (WLC) among cancer survivors reporting cognitive difficulties. Interventions were delivered weekly over 10 weeks. Feasibility was evaluated by recruitment, treatment adherence, and assessment completion. Subjective CRCD was assessed by the Functional Assessment of Cancer Therapy-Cognitive Function—Perceived Cognitive Impairment subscale (FACT-Cog PCI) and objective CRCD was assessed by the Hopkins Verbal Learning Test—Revised (HVLT-R). (3) Results: 32 participants (57.1% of eligible patients) were enrolled. All participants in acupuncture groups completed ≥8 of 10 treatments. Assessment completion rate was 100% for all participants. From baseline to week 10, the RA group (n = 19) reported a clinically meaningful 17.3-point increase in FACT-Cog PCI (95% confidence interval [CI] 12.5 to 22.1), compared to 9.7 points (95% CI 2.8 to 16.7) in the SA group (n = 9), and 6.8 points (95% CI −3.7 to 17.2) in the WLC group (n = 4). In the subgroup analysis among patients with a below-average baseline HVLT-R (T-score < 50), the RA group (n = 8) increased FACT-Cog PCI scores by 20.4 (95% CI 13.6 to 27.3), compared to 11.1 points (95% CI 0.6 to 21.5) in the SA group (n = 5). The improvements from RA persisted through week 16 in both the total sample and the sub-group. Eleven mild adverse events were reported, with pain and bleeding at the needling sites being the most common. (4) Conclusions: The findings support the feasibility and safety of conducting a randomized, placebo-controlled trial to evaluate acupuncture for cognitive dysfunction in cancer survivors.

23 December 2024 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
JSJared Silberlust
Jared Silberlust
KLKaitlin Harbour Lampson
Kaitlin Harbour Lampson
KHKatherine Han
Katherine Han
SLSusan Qing Li
Susan Qing Li
JMJun J. Mao
Jun J. Mao
KLKevin T T. Liou
Kevin T T. Liou

20 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LSLingyun Sun
Lingyun Sun
RFRose Wai-Yee Fok
Rose Wai-Yee Fok
JBJerrin Bawa
Jerrin Bawa
XLXiaotong Li
Xiaotong Li
KLKaitlin Harbour Lampson
Kaitlin Harbour Lampson
JMJun J Mao
Jun J Mao
Objective: Understanding immunity from the patient’s perspective is essential for optimizing cancer treatment and improving patient-reported outcomes. Currently, there are no established self-reported scales designed to assess immune vulnerability in cancer populations. We aimed to fill this gap by developing a brief scale fit for this purpose. Methods: We developed a five-item brief perceived immune vulnerability (PIV) scale and conducted a two-phase study on cancer survivors in China. In Phase 1, we assessed the reliability and factor structure of the PIV scale, while in Phase 2, we evaluated its construct validity by comparing it with measures of overall well-being and various patient characteristics. Results: Between October and December 2022, 100 patients completed Phase 1, while 1275 patients were enrolled in Phase 2. The mean age of the participants was 68.7 years (SD 10.3); 892 (64.9%) patients were female, and 537 (40.3%) patients had at least high-school education. In Phase 1, Cronbach’s α = 0.913, indicating good internal consistency. We identified one component with an eigenvalue of 3.72, explaining 70.17% of the variance. In Phase 2, patients reporting poor well-being had worse immune function (Pearson r = 0.202, p < 0.001). Additionally, patients undergoing active cancer treatment had worse immune function than those receiving survivorship care (p = 0.024). Meanwhile, patients with stage III/IV disease had worse immune function than those with stage I/II disease (p = 0.041). Conclusions: The PIV scale is a reliable and valid tool for assessing immune vulnerability in patients with cancer and preliminarily offers a convenient approach to monitoring and evaluating their self-reported immunity. Further research is needed to explore the broader utility of this instrument.